ArticleHIV/AIDS (Auckland, N.Z.)2025
Prevalence of Weight Gain and Associated Factors Among People Living with HIV 6- and 12-Months Post Dolutegravir-Based Anti-Retroviral Regimen Initiation in Gulu, Uganda; A Hospital-Based Retrospective Cohort Study.
Article in HIV/AIDS (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between High Serum Alanine Aminotransferase to High Density Lipoprotein Cholesterol Ratio and Metabolic Syndrome among People Living with HIV on Dolutegravir-Based ART in South-Western Uganda.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Dolutegravir (DTG), an integrase-strand transfer inhibitor approved by WHO in 2019 as part of first-line HIV treatment, has been linked to weight gain; however, data on this and its associated factors remain limited. Objective: This study aimed to determine the prevalence of weight gain and associated factors among people living with HIV (PLHIV) on DTG-based antiretroviral therapy (ART) regimens. Methods: We conducted a retrospective cohort study of PLHIV at St. Mary's Hospital Lacor between January 2020 and December 2021. Charts were reviewed for demographic and clinical data at baseline, at 6 months and at 12 months. Weight gain was defined as a ≥5% increase in weight from baseline at 6 months. Bivariate analysis followed by stepwise multivariable logistic regression was used to identify independent predictors of weight gain. Data were analyzed using STATA 17. Results: A total of 432 participants were included, 83.8% of whom were female. The median age was 44 years (IQR: 37.0-49.5). Most (97.0%) programmatically switched to DTG-based regimens. The prevalence of weight gain (defined as ≥5% increase from baseline) at 6 months was 7.4% (n=32/432) and 16.5% (n=31/187) at 12 months. Mean weight at baseline and 6 months was comparable (61.0 kg vs 60.0 kg, p=0.108), but a statistically significant increase in weight (p<0.001) and BMI (p<0.001) was observed from baseline to 12 months. On bivariate analysis, lower baseline WHO stage (p=0.048) and viral load <1000 copies/mL (p=0.009) were associated with weight gain; however, no factor remained significantly associated in multivariable analysis. Conclusion: Weight gain occured in approximately
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.